Establishment Labs Reports Fourth Quarter and Full Year 2024 Financial Results and Reaffirms 2025 Guidance
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2024 and reaffirmed 2025 guidance.
Establishment Labs to Present at TD Cowen's 45th Annual Health Care Conference
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in TD Cowen's 45th Annual Health Care Conference.
Establishment Labs to Present at Citi’s 2025 Unplugged Medtech and Life Sciences Access Day
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in a fireside chat at Citi's 2025 Unplugged Medtech and Life Sciences Access Day.
Establishment Labs Launches Preservé™
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction, announced it has launched Preservé™ in Brazil, the first country in its global rollout. Preservé is the second product in the Company’s minimally invasive platform, building upon the technologies and techniques developed with Mia Femtech®, Establishment Labs’ minimally invasive experience.
Establishment Labs to Announce Fourth Quarter 2024 Financial Results on February 26
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2024, after the market closes on Wednesday, February 26, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results.
Establishment Labs Announces CEO Transition
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José Chacón-Quirós has decided to retire as CEO, effective March 1, 2025. Peter Caldini, currently President of Establishment Labs, will serve as Interim CEO after that date.
Establishment Labs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 3:45 p.m. Pacific Time.
Establishment Labs Announces Participation in Upcoming Investment Conferences
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in three upcoming investment conferences.
Establishment Labs Announces $50 Million Registered Direct Offering
Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with select purchasers for the purchase of 765,696 common shares and pre-funded warrants to purchase up to 328,161 common shares in a registered direct offering for aggregate gross proceeds of approximately $50 million.
Establishment Labs Reports Third Quarter 2024 Financial Results
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2024.
Establishment Labs Announces Three-Year Mia Femtech Clinical Results at 9th World Symposium on Ergonomic Implants
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of three-year clinical results with Mia Femtech™ at the 9th Annual World Symposium on Ergonomic Implants (WSEI) being held this week in Barcelona, Spain.
Establishment Labs to Announce Third Quarter 2024 Financial Results on November 7
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.
Establishment Labs Publishes 2024 Post Market Surveillance Report
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced that it has published its 2024 Post Market Surveillance (PMS) Report.
First U.S. Women Successfully Receive Breast Augmentation with New FDA Approved Motiva Implants
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that the first patients in the United States have successfully undergone breast augmentation with Motiva® Implants.
Establishment Labs Receives U.S. FDA Approval for Motiva Implants
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced it has received approval from the U.S. Food and Drug Administration (FDA) for the use of Motiva® SmoothSilk® Ergonomix® and Motiva® SmoothSilk® Round breast implants in primary and revision breast augmentation.
Establishment Labs Reports Second Quarter 2024 Financial Results
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2024.
Establishment Labs to Announce Second Quarter 2024 Financial Results on August 6
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2024, after the market closes on Tuesday, August 6, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.
Findell Capital Management LLC Releases Comprehensive Research Coverage Report on Nasdaq:ESTAJune 18, 2024 - New York, NY - Findell Capital Management LLC, an investment management firm, today announced the release of a detailed Report on Establishment Labs Holdings Inc. (Nasdaq: ESTA), which can be found here .
Findell Capital Management LLC Releases Comprehensive Research Coverage Report on ESTA: NasdaqNew York, NY, June 17, 2024 – Findell Capital Management LLC, an investment management firm, today announced the release of a detailed Report on Establishment Labs Holdings Inc. (Nasdaq: ESTA), which can be found here.
Establishment Labs Announces Participation in Two Upcoming Investment Conferences
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences.
Establishment Labs Reports First Quarter 2024 Financial Results
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2024.
Establishment Labs Notes Presentation of 4-Year Results from Motiva U.S. IDE Study at The Aesthetic Meeting 2024
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, noted the presentation today of an update on the Motiva US IDE Study. The update will include four-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also an Investigator in the Study, will present the results at The Aesthetic Meeting 2024 in Vancouver, BC Canada.
Establishment Labs Announces Appointment of Jeff Ehrhardt as General Manager of North America
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America. After having spent over 25 years at Allergan Aesthetics, an Abbvie Company, Mr. Ehrhardt joins Establishment Labs with responsibilities including the anticipated launch of Motiva implants in the U.S. later this year.
Establishment Labs to Announce First Quarter 2024 Financial Results on May 8
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2024 after the market closes on Wednesday, May 8, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.
Establishment Labs Announces Participation in The Aesthetic Meeting 2024
Establishment Labs Holdings Inc. (
NASDAQESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in The Aesthetic Meeting 2024, which is being held May 2-5 in Vancouver, BC Canada.
